Objective: A systematic review/meta-analysis was conducted to investigate the effect of cannabinoid type-1 receptor (CB1R) regulation on the sleep-wake cycle of rats and to provide new ideas and evidence-based basis for clinical research on the treatment of sleep disorders.
Methods: We searched Cochrane Library, PubMed, Web of Science, Embase, Chinese Biomedicine Literature Database (CBM), China National Knowledge Infrastructure, WanFang, and VIP databases for relevant papers, about the effects of CB1R agonists/antagonists on sleep-wake cycle in rats, from inception to November 2023. Two reviewers performed study screening, data extraction, and risk of bias assessment using the SYRCLE’s risk of bias tool. Meta-analysis was performed using RevMan 5.3 software. Heterogeneity test was performed on the included studies (Test standard α = 0.1). I2 value was used to evaluate the heterogeneity. Forest plot was drawn, and p ≤ 0.05 indicates statistically significant difference.
Results: A total of 16 trials involving 484 experimental rats were included. The methodological quality evaluation results showed that the overall quality of the included studies was low. The results of the meta-analysis showed that single administration of CB1R agonists could shorten the wakefulness (W) time in the first 6 h (h) (standardized mean difference (SMD) = –2.52, 95% confidence interval (CI) (–3.83, –1.22), p = 0.0002) and 24 h (SMD = –0.84, 95% CI (–1.31, –0.36), p = 0.0005) after administration, prolong nonrapid eye movement sleep (NREM) time (SMD = 1.75, 95% CI (0.54, 2.95), p = 0.005) and rapid eye movement sleep (REM) time (SMD = 1.76, 95% CI (0.26, 3.26), p = 0.02), and increase REM frequency after administration (SMD = 1.67, 95% CI (0.98, 2.35), p < 0.00001), these results were all statistically different. There were no significant differences in sleep latency and average duration of REM. Single administration of CB1R antagonists prolonged the first 6 h W time after administration (SMD = 1.36, 95%CI (0.29, 2.43), p = 0.01), shortened the first 6 h NREM time (SMD = –1.73, 95% CI (–2.88, –0.57), p = 0.003) and REM time (SMD = –2.07, 95% CI (–3.17, –0.96), p = 0.0003) after administration, and increased the frequency of W after administration (SMD = 3.57, 95% CI (1.42, 5.72), p = 0.001). There was no statistical difference in the average duration of W. REM time and REM frequency increased after continuous CB1R agonist withdrawal.
Conclusions: According to the existing evidence, CB1R played a pivotal role in regulating the sleep-wake cycle in rats. CB1R agonists tended to reduce W time, increase NREM and REM sleep times, boost REM frequency, and promote sleep. Conversely, CB1R antagonists could increase the duration and frequency of W, shorten NREM and REM sleep times, and promote W.
| [1] |
GodosJ,GrossoG, CastellanoS,Galvano F,CaraciF,FerriR. Association between diet and sleep quality: a systematic review. Sleep Med Rev. 2021; 57: 101430.
|
| [2] |
Institute of Medicine (US) Committee on Sleep Medicine and Research. Sleep Disorders and Sleep Deprivation: An Unmet Public Health Problem. Colten HR,Altevogt BM, editors. Washington (DC): National Academies Press (US). 2006.
|
| [3] |
YangMMH,HartleyRL, LeungAA, et al. Preoperative predictors of poor acute postoperative pain control: a systematic review and meta-analysis. BMJ Open. 2019; 9(4),e025091.
|
| [4] |
HaackM,EngertLC, BesedovskyL, et al. Alterations of pain pathways by experimental sleep disturbances in humans: central pain-inhibitory, cyclooxygenase, and endocannabinoid pathways. Sleep. 2023; 46(6),zsad061.
|
| [5] |
MeyerN,HarveyAG, LockleySW,Dijk DJ. Circadian rhythms and disorders of the timing of sleep. Lancet. 2022; 400(10357),1061–1078.
|
| [6] |
SuraevAS,Marshall NS,VandreyR, et al. Cannabinoid therapies in the management of sleep disorders: a systematic review of preclinical and clinical studies. Sleep Med Rev. 2020; 53: 101339.
|
| [7] |
HuSS,MackieK. Distribution of the endocannabinoid system in the central nervous system. Handb Exp Pharmacol. 2015; 231: 59–93.
|
| [8] |
GaliègueS,Mary S,MarchandJ, et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem. 1995; 232(1),54–61.
|
| [9] |
Méndez-DíazM,Caynas-RojasS,Arteaga Santacruz V,Ruiz-ContrerasAE,Aguilar-RobleroR,Prospéro-García O. Entopeduncular nucleus endocannabinoid system modulates sleep-waking cycle and mood in rats. Pharmacol Biochem Behav. 2013; 107: 29–35.
|
| [10] |
BogáthyE,PappN, VasS,BagdyG, TóthfalusiL. AM-251, a cannabinoid antagonist, modifies the dynamics of sleep-wake cycles in rats. Front Pharmacol. 2019; 10: 831.
|
| [11] |
Pérez-MoralesM,De La Herrán-Arita AK,Méndez-Díaz M,Ruiz-ContrerasAE,Drucker-ColínR,Prospéro-García O. 2-AG into the lateral hypothalamus increases REM sleep and cFos expression in melanin concentrating hormone neurons in rats. Pharmacol Biochem Behav. 2013; 108: 1–7.
|
| [12] |
Murillo-RodríguezE,MachadoS,RochaNB, BuddeH,Yuan TF,Arias-CarriónO. Revealing the role of the endocannabinoid system modulators, SR141716A, URB597 and VDM-11, in sleep homeostasis. Neuroscience. 2016; 339: 433–449.
|
| [13] |
PavaMJ,Makriyannis A,LovingerDM. Endocannabinoid signaling regulates sleep stability. PLoS One. 2016; 11(3),e0152473.
|
| [14] |
HooijmansCR,RoversMM, de VriesRB,Leenaars M,Ritskes-HoitingaM. Langendam MW. SYRCLE’s risk of bias tool for animal studies. BMC Med Res Methodol. 2014; 14: 43.
|
| [15] |
TaoGC,ZhangN, ShangZZ, et al. Interpretation on examples of SYRCLE’ tool for interviewing risk of bias in animal experimentation. Chin J Evid-Based Cardiovasc Med. 2019; 11(03),292–295.
|
| [16] |
Herrera-SolísA,Vásquez KG,Prospéro-García O. Acute and subchronic administration of anandamide or oleamide increases REM sleep in rats. Pharmacol Biochem Behav. 2010; 95(1),106–112.
|
| [17] |
BogáthyE,PappN, TóthfalusiL,VasS,BagdyG. Additive effect of 5-HT2C and CB1 receptor blockade on the regulation of sleep-wake cycle. BMC Neurosci. 2019; 20(1),14.
|
| [18] |
Murillo-RodríguezE,CabezaR,Méndez-Díaz M,NavarroL,Prospéro-GarcíaO. Anandamide-induced sleep is blocked by SR141716A, a CB1 receptor antagonist and by U73122, a phospholipase C inhibitor. Neuroreport. 2001; 12(10),2131–2136.
|
| [19] |
Macías-TrianaL,Romero-Cordero K,Tatum-KuriA, et al. Exposure to the cannabinoid agonist WIN 55, 212-2 in adolescent rats causes sleep alterations that persist until adulthood. Eur J Pharmacol. 2020; 874: 172911.
|
| [20] |
Pérez-MoralesM,Fajardo-Valdez A,Méndez-Díaz M,Ruiz-ContrerasAE,Prospéro-GarcíaO. 2-Arachidonoylglycerol into the lateral hypothalamus improves reduced sleep in adult rats subjected to maternal separation. Neuroreport. 2014; 25(18),1437–1441.
|
| [21] |
Pérez-MoralesM,Alvarado-Capuleño I,López-Colomé AM,Méndez-Díaz M,Ruiz-ContrerasAE,Prospéro-GarcíaO. Activation of PAR1 in the lateral hypothalamus of rats enhances food intake and REMS through CB1R. Neuroreport. 2012; 23(14),814–818.
|
| [22] |
PuskarP,Sengupta T,SharmaB,NathSS,MallickH, AkhtarN. Changes in sleep-wake cycle after microinjection of agonist and antagonist of endocannabinoid receptors at the medial septum of rats. Physiol Behav. 2021; 237: 113448.
|
| [23] |
RenWT. Effect of (m)VD-Hpα a cannabinod receptor typel agonist, on sleep-wak. states in rats. Lanzhou university. 2016.
|
| [24] |
CalikMW,CarleyDW. Effects of cannabinoid agonists and antagonists on sleep and breathing in Sprague-Dawley Rats. Sleep. 2017; 40(9),zsx112.
|
| [25] |
CalikMW,CarleyDW. DMSO potentiates the suppressive effect of dronabinol on sleep apnea and REM sleep in rats. J Cannabis Res. 2023; 5(1),30.
|
| [26] |
XieJF,WangLX, RenWT, et al. An α-hemoglobin-derived peptide (m)VD-hemopressin (α) promotes NREM sleep via the CB1 cannabinoid receptor. Front Pharmacol. 2023; 14: 1213215.
|
| [27] |
GoonawardenaAV,PlanoA, RobinsonL,Platt B,HampsonRE,RiedelG. A pilot study into the effects of the cb1 cannabinoid receptor agonist WIN55, 212-2 or the antagonist/inverse agonist AM251 on sleep in rats. Sleep Disord. 2011; 2011: 178469.
|
| [28] |
LowZXB,LeeXR, SogaT,Goh BH,AlexD, KumariY. Cannabinoids: emerging sleep modulator. Biomed Pharmacother. 2023; 165: 115102.
|
| [29] |
Petrunich-RutherfordML,Calik MW. Effects of cannabinoid agonists and antagonists on sleep in laboratory animals. Adv Exp Med Biol. 2021; 1297: 97–109.
|
| [30] |
MontiJM,Pandi-Peumal SR. Murillo-Rodriguez E. Cannabinoids and sleep—molecular, functional and clinical aspects. Springer Nature. 2021: 1297.
|
| [31] |
Méndez-DíazM,Ruiz-ContrerasAE,Cortés-Morelos J,Prospéro-García O. Cannabinoids and sleep/wake control. Adv Exp Med Biol. 2021; 1297: 83–95.
|
| [32] |
LiedhegnerES,SasmanA, HillardCJ. Brain region-specific changes in N-acylethanolamine contents with time of day. J Neurochem. 2014; 128(4),491–506.
|
| [33] |
MoherD,Liberati A,TetzlaffJ,AltmanDG,PRISMAGroup. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6(7),e1000097.
|
RIGHTS & PERMISSIONS
2024 The Author(s). Journal of Evidence-Based Medicine published by Chinese Cochrane Center, West China Hospital of Sichuan University and John Wiley & Sons Australia, Ltd.
PDF
